Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses

Yong Liu; Xiangwei Zhang; Zhaofei Pang; Yadong Wang; Haotian Zheng; Guanghui Wang; Kai Wang; Jiajun Du

doi:doi:10.18632/aging.205838

← Back

Research Paper Volume 16, Issue 10 pp 8772—8809

Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses

Figure 9. Tumor mutation burden (TMB) and drug sensitivity analysis. (A) The correlation of MPPS and TMB in TCGA-LUAD samples. (B) The differences of TMB between the high- and low-risk groups. (C) The Kaplan–Meier curves show OS differences stratified by TMB and MPPS. Visualization of the top 20 gene mutations in high-risk group (D) and low-risk group (E). (F) The sensitivity of 117 drugs between the high- and low-risk groups. P < 0.05 was considered as statistical significance.